Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target

Absci Corp

Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.
Total deal consideration up to $247M, including upfront, R&D funding, milestones, plus royalties on sales.
Agreement combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
Platform aims to reduce drug design-validation cycle to ~6 weeks and expand target universe to GPCRs, ion channels.
Collaboration follows Absci's recent publication on 'zero-shot' generative AI model for de novo antibody design.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.